TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants WESTMINSTER, CO -- (BUSINESS WIRE)

TriSalus Life Sciences Announces Expiration

and Results of Exchange Offer and

Consent Solicitation Relating to Warrants

WESTMINSTER, CO -- (BUSINESS

WIRE) - June 26, 2024 -- TriSalus Life Sciences Inc. ("TriSalus" or the "Company") (Nasdaq:

TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver

and pancreatic tumors, announced today the expiration and results of its previously announced exchange offer (the "Offer")

and consent solicitation (the "Consent Solicitation") relating to its warrants (the "Warrants") identified in

the Prospectus/Offer to Exchange that forms a part of the Registration Statement (as defined below). The Offer and Consent Solicitation

expired one minute after 11:59 p.m., Eastern Standard Time, on June 25, 2024.

Pursuant to the Offer, the

Company offered all holders of each class of its Warrants, consisting of (i) its publicly-traded Warrants (the "Public Warrants"),

(ii) certain Warrants issued in a private placement transaction occurring simultaneously with the closing of the initial public offering

of the Company (the "Private Placement Warrants") and (iii) certain Warrants issued for working capital requirements and payment

of certain expenses of the Company ("Working Capital Warrants"), the opportunity to receive 0.30 shares of the Company's

common stock, par value $0.0001 per share ("Common Stock"), in exchange for each Warrant tendered by the holder and exchanged

pursuant to the Offer. As previously disclosed, parties representing approximately 34.8% of the Public Warrants agreed to tender their

Public Warrants in the Offer and to consent to the Warrant Amendment (as defined below) in the Consent Solicitation pursuant to tender

and support agreements. The Company did not receive tender and support agreements with respect to the Private Placement Warrants or Working

The Offer and Consent Solicitation

expired at one minute after 11:59 p.m., Eastern Standard Time, on June 25, 2024. The Company has been advised that the Warrants tendered

were comprised of 6,533,614 Public Warrants (including 9,185 Public Warrants tendered through guaranteed delivery), 504,685 Private Placement

Warrants, and 0 Working Capital Warrants, which represents approximately 78.89%, 10.23% and 0.00% of the outstanding Warrants of each

respective class, were validly tendered and not validly withdrawn prior to the expiration of the Offer and Consent Solicitation. The Company

expects to accept all validly tendered Warrants for exchange and settlement on or before July 1, 2024.

In addition, pursuant to

the Consent Solicitation, the Company received the approval of approximately 78.89% of the outstanding Public Warrants to amend the warrant

agreement that governs the Warrants (the "Warrant Amendment"), which represents a majority of the outstanding Public Warrants

required to effect the Warrant Amendment with respect to the Public Warrants. Pursuant to the Consent Solicitation, the Company did not

receive the requisite approval to effect the Warrant Amendment with respect to either the Private Placement Warrants or Working Capital

Warrants. Accordingly, the Company and Continental Stock Transfer & Trust Company entered into the Warrant Amendment, dated June 26,

2024, with respect to the Public Warrants but not the Private Placement Warrants or Working Capital Warrants.

The Company also announced

that its Registration Statement on Form S-4 (Registration No. 333- 279691), filed with the U.S. Securities and Exchange Commission (the

"SEC") on May 24, 2024 (the "Registration Statement"), registering shares of Common Stock issuable in the Offer

and pursuant to the Warrant Amendment was declared effective by the SEC on June 25, 2024.

Oppenheimer & Co. Inc.

served as the Dealer Manager and Solicitation Agent for the Offer and Consent Solicitation. Morrow Sodali LLC served as the Information

Agent for the Offer and Consent Solicitation, and Continental Stock Transfer & Trust Company served as the Exchange Agent.

About TriSalus Life Sciences

TriSalus Life Sciences

is an oncology focused medical technology business providing disruptive drug delivery technology with the goal of improving therapeutics

delivery to liver and pancreatic tumors.

The Company's platform

includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company's

two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD ) approach to deliver a range of therapeutics:

the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for

pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.

The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired

delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company's investigational immunotherapeutic

candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can

make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology

(PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver

and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by PEDD are

commonly present as well. Nelitolimod delivered by PEDD will be studied across several indications in an effort to address immune dysfunction

and overcome drug delivery barriers in the liver and pancreas.

In partnership with leading

cancer centers across the country - and by leveraging deep immuno-oncology expertise and inventive technology development -

X (formerly Twitter) and LinkedIn.

No Offer or Solicitation

This press release shall

not constitute an offer to exchange or the solicitation of an offer to exchange or the solicitation of an offer to purchase any securities,

nor shall there be any exchange or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful

prior to registration or qualification under the securities laws of any such jurisdiction. The Registration Statement filed with the SEC

registering shares of Common Stock issuable in the Offer and pursuant to the Warrant Amendment was declared effective by the SEC on June

Forward-Looking Statements

Certain statements made

in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section

21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby under the Private Securities

Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "expect," "will"

or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These

forward-looking statements may include, but are not limited to, statements regarding the Company's acceptance of all validly tendered

Warrants for exchange of shares of Common Stock in the Offer and settlement thereof. These statements are based on various assumptions,

whether or not identified in this press release, and on the current expectations of the Company's management and are not predictions

of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as,

and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability.

Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances

are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including,

without limitation: the Company's ability to successfully accept all validly tendered Warrants for exchange of shares of Common

Stock; the uncertainty as to whether the Company will exercise its right to force exchange the Public Warrants pursuant to the Warrant

Amendment in the future; risks related to future market adoption of the Company's offerings; risks related to the Company's

marketing and growth strategies; risks associated with clinical development and regulatory approval

of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data

generated during the Company's clinical trials, the cost and timing of all development activities and clinical trials, unexpected

safety and efficacy data observed during clinical studies, changes in expected or existing competition or market conditions, changes in

the regulatory environment, unexpected litigation or other disputes, the

effects of competition on the Company's future business; the risks discussed in the Company's quarterly report on Form 10-Q

for the period ended March 31, 2024 under the heading "Risk Factors"; and the risks discussed in the Company's Registration

Statement, under the heading "Risk Factors" and other documents of the Company filed, or to be filed, with the SEC. If any

of these risks materialize or any of the Company's assumptions prove incorrect, actual results could differ materially from the

results implied by these forward-looking statements. There may be additional risks that the Company presently does not know of or that

the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking

statements. In addition, forward-looking statements reflect the Company's expectations, plans or forecasts of future events and

views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company's

assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the

Company specifically disclaims any obligation to do so except as required by applicable law. These forward-looking statements should not

be relied upon as representing the Company's assessments as of any date subsequent to the date of this press release. Accordingly,

undue reliance should not be placed upon the forward-looking statements.

For Media and Investor Inquiries: